NEW YORK – Cofactor Genomics said Friday that its machine learning-based predictive diagnostic assay OncoPrism has received coverage from Medicare administrative contractor Palmetto GBA.
The test evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's response to immune checkpoint inhibitor (ICI) immunotherapy.
The coverage decision is for patients with recurrent and metastatic head and neck squamous cell carcinoma (RM-HNSCC) who are being considered for ICI immunotherapy either as a single agent or in combination with chemotherapy, Cofactor said in a statement.
The coverage "is a win for all those working tirelessly to bridge the precision medicine gap in immunotherapy," Cofactor Genomics CEO Jarret Glasscock said in a statement. "Most importantly, this is a win for cancer patients. More accurate prediction of response results in more informed treatment prioritization and better patient outcomes."
The firm noted that RM-HNSCC is one of 11 solid tumor cancers being studied in the multicenter national clinical trial PREDAPT to evaluate OncoPrism's ability to predict patient response to ICI.